CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant
Bothell (euro adhoc) -
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
professional career
BOTHELL, Wash., May 20 -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) today announced the appointment of Jay H. Traverse, M.D., FACC, FAHA, to its Scientific Advisory Board as a clinical consultant. Traverse is an interventional cardiologist with the Minneapolis Heart Institute at Abbott Northwestern Hospital with extensive experience in cardiovascular stem cell clinical trial research. "We are delighted to welcome Dr. Traverse to our Scientific Advisory Board," said Ronald W. Berninger, Ph.D., Chief Scientific Officer at CellCyte. "His experience and knowledge will be a tremendous asset to CellCyte as we develop and implement our clinical trial strategy for our lead compound, CCG-TH30."
Dr. Traverse received his M.D. from Case Western Reserve University Medical School and is currently an Interventional Cardiologist and Associate Professor of Medicine in the Department of Cardiology at the University of Minnesota. He joined the Minneapolis Heart Institute immediately upon finishing his training in 1996. His clinical interests include cell therapy administration in chronic ischemic heart disease and following acute myocardial infarction, angiogenesis and mitigation of reperfusion injury. Traverse is a member of numerous professional associations including American College of Cardiology (ACC), Society for Cardiac Angiography and Interventions (SCAI), American Heart Association's (AHA) Council on Basic Cardiovascular Science, and the American Physiological Society.
About CellCyte Genetics
CellCyte Genetics is a biotechnology company engaged in the discovery,
development and commercialization of stem cell enabling therapeutic products.
CellCyte is developing products designed to allow more efficient delivery and
increased retention of adult stem cells to diseased organs, such as the heart.
The goal of these therapies is to increase the number of stem cells delivered to
a damaged organ, thereby markedly increasing organ healing and functional
restoration. The Company's lead product in development, CCG-TH30, is designed to
send autologous bone marrow-derived (adult) stem cells to the heart of patients
after a heart attack.CellCyte Genetics | 1725 220th Street SE | Bothell | Washington | 98021 | US
For further information see: www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS
DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED,
AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE
FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS,
EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL
INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN
FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES
THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS,
PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS
THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY,
FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE,"
"PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS
AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS
ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF CCG-TH30. OTHER RISKS INCLUDE
RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS AND
COMPANIES AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND
DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT
EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE,
AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS,
OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN
THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS,
PLANS, EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE
REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR
INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE
INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED
IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME TO TIME WITH THE UNITED STATES
SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT REPORTS
ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT
OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD,
THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS
NEWS RELEASE.SOURCE CellCyte Genetics Corporation
end of announcement euro adhoc
Further inquiry note:
Investor Relations of CellCyte Genetics Corporation,
+1-877-688-5050, Investorrelations@cellcyte.com
Branche: Biotechnology
ISIN: US15116P1030
WKN: A0MLCV
Börsen: Börse Frankfurt / Open Market
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade